Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Terminated 3Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 49Lymphoid 49Other hematologic neoplasm 32Myeloid 6Genitourinary 5Gastrointestinal 4Dermatologic 4Thoracic 3Gynecologic 3CNS 2Tumor-Agnostic 1Sarcoma 1Classical hematology 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Lenalidomide × Gynecologic × Clear all
NCT00903630 2017-12-28

Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Masonic Cancer Center, University of Minnesota

Phase 1/2 Terminated
15 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01202890 2014-01-08

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

New Mexico Cancer Research Alliance

Phase 1 Terminated
1 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00179725 2006-04-12

Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Celgene

Phase 1/2 Terminated
60 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡